$IPA is currently trading on the Nasdaq at $6.16 a share.
24.84M shares outstanding
$153M Market Cap
ImmunoPrecise is an antibody discovery company that offers pre-clinical drug development services to the Pharma and biotech industry. This part of the business does $15M in revenue and continues to grow and will start to accelerate with their recent acquisition of BioStrand (AI tech). An exciting part of IPA is their wholly owned subsidiary called Talem Therapeutics. Talem is their internal pipeline of antibody drug programs that will be out-licensed to Big Pharma for upfront money and royalties sometime during the preclinical stage. Upfront payments can be anywhere from $10M-$100M+ and royalties of 3%-12%+. An out-licensing deal will be a significant event for this company as it will validate their platforms to the market and demand a sharp rerate in valuation.
In April, IPA completed the acquisition of BioStrand, an AI software company for genomic analysis. This has potential to be a game changer not only for IPA but the biotech industry as it will expedite the drug discovery process. Taking projects that usually take monthsyears down to daysweeks.
IPA is a much safer biotech investment as they have recurring revenues from the CRO business which gives downside protection + Talem Therapeutics and BioStrand provide the blue sky optionality. A licensing deal for a Talem asset or BioStrand partnership will easily 5x the stock.
$IPA has recently broke out and has closed above 200MA last 7 trading days.
Leave a Reply